CHMP positive for extension of indication of Cibingo (abrocitinib) to include treatment of adolescents aged 12 years and older with atopic dermatitis.- Pfizer
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Cibinqo. The marketing authorisation holder for this medicinal product is Pfizer Europe MA
The CHMP adopted an extension to the existing indication to include treatment of adolescents aged 12 years and older. For information, the full indication will therefore be as follows: "Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy".
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins